Ambit Biosciences
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
4215 Sorrento Valley Blvd, San Diego, Ca...Phone Number
(858) 334-2100Website
www.ambitbio.comRevenue
$25.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Ambit Biosciences
Ambit Biosciences Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of drugs targeting unmet medical needs in oncology, autoimmune, and inflammatory diseases through kinase inhibition. Their product pipeline includes several programs, with quizartinib being the lead candidate, a once-daily oral FLT3 kinase inhibitor for acute myeloid leukemia. The company leverages its expertise in kinase research to develop a sustainable pipeline of small molecule inhibitors. Ambit also offers profiling services and clinical development expertise, positioning itself as a partner of choice in the kinase domain.Explore more
Ambit Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ambit Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Ambit Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Ambit Biosciences recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Ambit Biosciences launches new products
Check if Ambit Biosciences has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Ambit Biosciences
Check out if Ambit Biosciences is spiking on competitors!
Funding: Get notified immidiatlly once Ambit Biosciences has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Ambit Biosciences had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Ambit Biosciences as Masked Content
Find 2 more new buyers
Compare Similar Companies to Ambit Biosciences
Compare insights from companies similar to Ambit Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ambit Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ambit Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ambit Biosciences.
Ambit Biosciences Tech Stack
A closer look at the technologies used by Ambit Biosciences
Ambit Biosciences News & Media
Daiichi Sankyo to Acquire Ambit Biosciences
Lead Compound, Quizartinib, Will Further Build Daiichi Sankyo Oncology Pipeline TOKYO and SAN DIEGO, Sept. 29, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) (TSE: 4568) and Ambit Biosciences (NASDAQ: AMBI), jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger withAmbit Announces Participation At Baird 2014 Health Care Conference
SAN DIEGO, Aug. 27, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Baird 2014 Health Care Conference to be held at The New York Palace Hotel in New York City on September 3-4, 2014. Alan Fuhrman, Ambit's CFO, will provide an overview of the Company and its lead drug candidate, quizartinib,Ambit Biosciences Announces Second Quarter 2014 Operating Results
SAN DIEGO, Aug. 12, 2014 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced operating results for the second quarter 2014. The company will host a conference call today to discuss financial results for the quarter and to provide an operational update for the first half of 2014. "We are pleased to have initiated our QUANTUM-R Phase 3Ambit Biosciences To Announce Second Quarter 2014 Financial Results
SAN DIEGO, July 29, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report second quarter operational results after closing of the NASDAQ Global Market on Tuesday, August 12, 2014. A conference call hosted by Michael Martino, president and CEO, and other members of senior management will take place on the same day at 5:00
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ambit Biosciences
Sign Up For FreeTo access detailed company insights
Ambit Biosciences Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of drugs targeting unmet medical needs in oncology, autoimmune, and inflammatory diseases through kinase inhibition. Their product pipeline includes several programs, with quizartinib being the lead candidate, a once-daily ora... Read More
